United Therapeutics Stock Forecast
NASDAQ: UTHRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
UTHR analyst consensus
Consensus (15 analysts)
buy
Avg. price target
$649.64+21.93%
- Strong buy 3
- Buy 8
- Hold 3
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 15 Wall Street analysts covering United Therapeutics (2026-10-07), 11 rate the stock a buy or strong buy, 3 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $649.64, with a high estimate of $728.00 and a low estimate of $321.00. The average target implies upside of 21.9% from the current price of $532.78.
The spread between the highest and lowest targets is 126.8%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for UTHR.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 20% |
| Buy | 8 | 53% |
| Hold | 3 | 20% |
| Sell | 1 | 7% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $321.00 | -39.75% |
| Average target | $649.64 | +21.93% |
| High target | $728.00 | +36.64% |